Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01930955
Other study ID # AURI
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date August 1, 2011
Est. completion date December 30, 2022

Study information

Verified date February 2021
Source Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Some acute upper respiratory tract infection(AURI) in children is characterized by fever and vomiting,and it is one common reason for visiting a pediatrician. White blood count(WBC) usually increased in this children patients,hence antibiotics are often prescribed properly assumed. In the present study, it was hypothesized that it was not necessary to prescribe amoxicillin for the children.


Description:

After inclusion of eligible children patients,one group was prescribed amoxicillin,and another not.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 30, 2022
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year to 3 Years
Eligibility Inclusion Criteria: - Acute upper respiratory tract infection - Fever - Vomiting - Increased white blood cell Exclusion Criteria: - 0ther symptoms of digestive system - Headache

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amoxicillin
ß-lactam antibiotics

Locations

Country Name City State
China Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other white cell count White cell count decreased in 90% participants. 3 days
Primary fever Fever stopped or mitigated in 90% participants. 3 days
Secondary vomiting Vomiting stopped or mitigated in 90% participants. 2 days
See also
  Status Clinical Trial Phase
Completed NCT01537081 - Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections Phase 2/Phase 3
Completed NCT05879393 - The Multistrain Probiotic OMNi-BiOTiC® Active for Upper Respiratory Tract Infections in Older People N/A
Completed NCT04611061 - Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers
Recruiting NCT03827590 - Clinical Trials to Assess the Efficacy and Safety of HLIM Phase 3
Completed NCT05134766 - Retrospective Evaluation of Clinical, Virological and Serological Data in Patients With Mild Acute Upper Respiratory Tract Infections
Not yet recruiting NCT03218696 - Comparison of a Protective Cough Syrup Against Placebo on Night Cough in Children 1-5 Years Coughing Since 1- 2 Days Due to Common Cold N/A
Completed NCT04626622 - Kagocel® for the Prevention of ARVI and Influenza in Young People
Completed NCT05214677 - A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809 Phase 1
Completed NCT05214690 - A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2 Phase 1